Processing

Please wait...

Settings

Settings

Goto Application

1. WO1997029749 - THERAPEUTIC AGENT FOR KIDNEY DISEASES

Publication Number WO/1997/029749
Publication Date 21.08.1997
International Application No. PCT/JP1997/000439
International Filing Date 19.02.1997
Chapter 2 Demand Filed 19.09.1997
IPC
A61K 31/517 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/55 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
C07D 401/14 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
CPC
A61K 31/517
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/5377
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
5377not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/541
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
541Non-condensed thiazines containing further heterocyclic rings
A61K 31/55
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 13/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
12of the kidneys
C07D 401/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14containing three or more hetero rings
Applicants
  • KYOWA HAKKO KOGYO CO., LTD. [JP]/[JP] (AllExceptUS)
  • FUJIWARA, Shigeki [JP]/[JP] (UsOnly)
  • OKAMURA, Yuko [JP]/[JP] (UsOnly)
  • TAKAI, Haruki [JP]/[JP] (UsOnly)
  • NONAKA, Hiromi [JP]/[JP] (UsOnly)
  • MORIYAMA, Takahiro [JP]/[JP] (UsOnly)
  • YAO, Kozo [JP]/[JP] (UsOnly)
  • KARASAWA, Akira [JP]/[JP] (UsOnly)
Inventors
  • FUJIWARA, Shigeki
  • OKAMURA, Yuko
  • TAKAI, Haruki
  • NONAKA, Hiromi
  • MORIYAMA, Takahiro
  • YAO, Kozo
  • KARASAWA, Akira
Priority Data
8/3041119.02.1996JP
Publication Language Japanese (JA)
Filing Language Japanese (JA)
Designated States
Title
(EN) THERAPEUTIC AGENT FOR KIDNEY DISEASES
(FR) AGENT THERAPEUTIQUE CONTRE LES MALADIES RENALES
Abstract
(EN)
A therapeutic agent for kidney diseases which comprises as the active ingredient a quinazoline derivative represented by general formula (I) or a pharmacologically acceptable salt thereof, wherein R1 represents hydrogen, lower alkyl, alkenyl, aralkyl, etc.; R2, R3, R4, and R5 may be the same or different and each represents hydrogen, lower alkyl, lower alkoxy, lower alkanoyl, etc.; R6, R7, R8, and R9 may be the same or different and each represents hydrogen, lower alkyl, lower alkoxy, aralkyloxy, lower alkanoyloxy, etc., or adjacent two of these may be bonded to each other to thereby form methylenedioxy, etc.; R10 represents hydrogen, lower alkyl, etc.; R11 and R12 may be the same or different and each represents hydrogen, lower alkyl, cycloalkyl, phenyl, aralkyl, etc., or R11 and R12 may be bonded to each other to thereby form a heterocycle with the nitrogen atom; and n is 0, 1, or 2. The therapeutic agent is useful for the prevention or treatment of kidney diseases such as nephritis and diabetic nephropathy.
(FR)
Cette invention concerne un agent thérapeutique destiné au traitement des maladies rénales. Ledit agent comporte en tant qu'ingrédient actif un dérivé de quinazoline représenté par la formule générale (I) ou un sel pharmaceutiquement acceptable de ce dérivé. Dans la formule (I), R1 représente hydrogène, alkyle inférieur, alcényle, aralkyle, etc., R2, R3, R4 et R5 peuvent être identiques ou différents et chacun représente hydrogène, alkyle inférieur, alcoxy inférieur, alcanoyl inférieur, etc., R6, R7, R8 et R9 peuvent être identiques ou différents et chacun représente hydrogène, alkyle inférieur, alcoxy inférieur, aralkyloxy, alcanoyloxy, etc. ou adjacents, deux de ces éléments pouvant être liés l'un à l'autre de façon à former un méthylènedioxy, etc., R10 représente hydrogène, alkyle inférieur, etc., R11 et R12 peuvent être identiques ou différents et chacun représente hydrogène, alkyle inférieur, cycloalkyle, phényle, aralkyle, etc. ou R11 et R12 peuvent être liés l'un à l'autre de façon à former un hétérocycle avec l'atome d'azote et n est égal à 0, 1 ou 2. Ledit agent thérapeutique est utile à la prévention ou au traitement des maladies rénales telles que la néphrite et la néphropathie diabétique.
Latest bibliographic data on file with the International Bureau